p38 MAPK

Applications Doramapimod is a highly potent inhibitor of p38 mitogen-activated protein kinase (MAPK). Doramapimod is a potential agent for the treatment of inflammatory diseases. Doramapimod blocks baseline and bortezomib-triggered upregulation of p38 MAPK and Hsp27 phosphorylation leading to enhanced cytotoxicity and caspase activation.
References Pargellis, C. et al.: Nat. Struct. Biol., 9, 268 (2002,); Kuma, Y. et al.: J. Biol. CHem., 280, 19472 (2005); Yasui, H. et al.: Br. J. Haematol., 136, 414 (2007);

Applications TGX-221 is a potent, selective, and cell permeable inhibitor of Phosphatidylinositol 3-kinase (PI3K) p110β.
References Chaussade, C., et al.: Biochem. J., 404, 449 (2007); Straub, A., et al.: Thromb Haemost., 99, 609 (2008); Lu, X., et al.: Appl. Microbiol. Biotechnol., 89, 1423 (2011); Bird, J., et al.: Thromb Res., 127, 560 (2011); Jackson, S., et al.: Nat. Med., 11, 507 (2005)

Applications VX 745 is a potent and selective inhibitor of p38α mitogen-activated protein (MAP) kinase. VX 745 is a potential anti-inflammatory agents. Studies suggest that VX 745 may be useful in the treatment of Werner syndrome.
References Haddad, J.J.: Curr. Opin. Invest. Drugs, 2, 1070 (2001); Duffy, J.P. et al.: ACS Med. Chem. Lett., 2, 758 (2011); Bagley, M.C. et al.: Pharmaceuticals, 3, 1842 (2010);

Applications 3-Methyl Adenine is a selective autophagy and phosphoinositide 3-kinase (PI3K) inhibitor (1,2,3). 3-MA inhibits autophagy by blocking autophagosome formation via the inhibition of type III Phosphatidylinositol 3-kinases (PI-3K).
References (1) Munafo, D., et al.: J. Cell Sci., 114, 3619 (2001) (2) Aggarwal, B., et al.: Biochem. Pharmacol., 71, 1397 (2006) (3) Hayat, M., et al.: Oncologist, 12, 20 (2007)

Applications AS-252424 is a novel, potent, and selective phosphoinositide 3-kinase gamma (PI3Kγ) inhibitor. It is also an inhibitor of Casein kinase and PI3K p110α.
References Pomel, V., et al.: J. Med. Chem., 49, 3857 (2006); Edling, C.E., et al.: Clin. Cancer Res., 16, 4928 (2010); Condliffe, A.M., et al.: Blood, 106, 1432 (2005)

Applications SB 202190 is a DFG inhibitor used in the treatment of colorectal cancer. It is a highly selective, potent inhibitor of p38 MAP kinase. SB-202190 is able to promote proliferation of C6 cells in lower concentration but induced apoptosis in higher levels. Studies show that SB202190 can protect neural function from ischemia/reperfusion injury and regulate the activation of Bcl-2 and Bax protein after ischemia/reperfusion in rat.
References Grossi, V. et al.: Canc. Biol. Ther., 13, 1471 (2012); Chen, Y. et al.: Med. Sci. Mon., 18, BR383 (2012); Horstmann, S. et al.: J. Neurosci. Res., 52, 483 (1998); Zhang, F. et al.: Zhong. Yao. Tong., 18, 512 (2002); Wang, J. et al.: Nanj. Yike Dax. Xue., 29, 840 (2009);

Applications LY 294002 Hydrochloride is a highly selective inhibitor of Phosphatidylinositol 3-kinase (PI3K). It is a salt analogue of LY 294002 (L486590).
References Lin, C., et. al.: J. Biol. Chem., 286, 10483 (2011); Cao, H., et. al.: J. Biol. Chem., 288, 30399 (2013);